Guangdong Lantai-Viewland Pharmaceutical

Guangdong Lantai-Viewland Pharmaceutical, also known as Viewland Pharm, is a Chinese pharmaceutical company based in Guangzhou, Guangdong. Established in the 1990s, the company specializes in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), intermediates, veterinary products, and pesticides. Viewland Pharm also provides custom synthesis, contract research, and turn-key technology services for pharmaceutical machinery and packaging. In 2007, the company gained international attention by licensing the HIV drug candidate MIV-160 from Medivir AB, although the rights were later transferred to Beijing Mefuvir. Today, the company operates as a comprehensive service provider and supplier in the global pharmaceutical supply chain, offering a wide range of products and technical support for regulatory affairs.